Effect of SGLT2 inhibitor, canagliflozin, for the size of lipid particles

Effect of SGLT2 inhibitor, canagliflozin, for the size of lipid particles - Effect of canagliflozin for the size of lipid particles

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020027

Enrollment

Registered

2016-02-01

Start date

2016-01-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

To prescribe canagliflozin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients of type 2 diabetes with HbA1c>=7.0 2)Paitents over 20 years old and under 75 years old 3)Patients give written informed consent

Exclusion criteria

Exclusion criteria: 1) History of hypersensitivity of canagliflozin 2) Severe ketosis, diabetic coma or precoma 3) Severe infection, pre or post surgery, or severe trauma 4) Patients taking fibrate-based medicines or pioglitazone 5) Patients taking diuretic medicines 6) eGFR < 45 mL/min/1.73 m2 or artificial dialysis 7) Considered as inadequate by the investigator

Design outcomes

Primary

Measure	Time frame
Change of the data of 20 lipoproteins fractions measured by high-performance gel permeation chromatography at 3 months after canagliflozin administration	—

Secondary

Measure	Time frame
1) Change of hemoglobin A1c (HbA1c) for 3 months at 3 months after canagliflozin administration 2) Change of body mass and body mass index (BMI) at 3 months after canagliflozin administration 3) Change of blood biochemical value at 3 months after canagliflozin administration	—

Countries

Japan

Contacts

Public ContactMasayuki Yoshida

Tokyo Medical and Dental University Medical Genetics/ Geriatrics

masavasc@tmd.ac.jp03-5803-4617

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026